Clinical trial / 2020
Nicotinamide riboside supplementation increased fat-free mass and muscle acetylcarnitine but did not alter insulin sensitivity in overweight or obese adults.
In a randomized, double-blinded, placebo-controlled crossover study, 13 healthy overweight or obese adults received 1000 mg/d nicotinamide riboside (NR) and placebo for 6 weeks each. NR increased skeletal muscle markers of NAD+ synthesis, body fat-free mass (62.65% ± 2.49% vs 61.32% ± 2.58%; change: 1.34% ± 0.50%, P = 0.02), and sleeping metabolic rate. Skeletal muscle acetylcarnitine concentrations increased (4558 ± 749 vs 3025 ± 316 pmol/mg dry weight; change: 1533 ± 683, P = 0.04), along with exercise acetylcarnitine-forming capacity (P = 0.01). However, NR had no effects on insulin sensitivity, mitochondrial function, hepatic/intramyocellular lipid accumulation, cardiac energy status, cardiac ejection fraction, blood pressure, inflammation markers, or energy metabolism.
- Study type
- Randomized, double-blinded, placebo-controlled, crossover trial
- Who was studied
- 13 healthy overweight or obese men and women
- What was measured
- Insulin sensitivity, mitochondrial function, body composition, and metabolic parameters
THE PAPER
Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans.
Remie CME, Roumans KHM, Moonen MPB, Connell NJ, Havekes B, Mevenkamp J, Lindeboom L, de Wit VHW, van de Weijer T, Aarts SABM, Lutgens E, Schomakers BV, Elfrink HL, Zapata-Pérez R, Houtkooper RH, Auwerx J, Hoeks J, Schrauwen-Hinderling VB, Phielix E, Schrauwen P. Am J Clin Nutr, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.